title: A case of type 2B von Willebrand disease reverse to normal when treated with high doses of protease inhibitor.
authors.forename: Y S
authors.initials: YS
authors.lastname: Arkel
authors.forename: D H
authors.initials: DH
authors.lastname: Ku
authors.forename: C
authors.initials: C
authors.lastname: Lake
authors.forename: L
authors.initials: L
authors.lastname: Pasquale
authors.forename: X
authors.initials: X
authors.lastname: Lam
authors.forename: D
authors.initials: D
authors.lastname: Gibson
authors.forename: S
authors.initials: S
authors.lastname: Burstin
mesh_terms: D019943:Amino Acid Substitution; D001704:Biopolymers; D005260:Female; D006801:Humans; D019888:Nelfinavir / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects; D017354:Point Mutation; D011182:Postoperative Care; D011300:Preoperative Care; D011480:Protease Inhibitors / Q000627:therapeutic use*; D017434:Protein Structure, Tertiary; D012310:Ristocetin / Q000494:pharmacology; D014842:von Willebrand Diseases / Q000188:drug therapy* / Q000235:genetics; D014841:von Willebrand Factor / Q000737:chemistry / Q000235:genetics
chemical_list: D001704:Biopolymers; D011480:Protease Inhibitors; D014841:von Willebrand Factor; D012310:Ristocetin; D019888:Nelfinavir